Their data demonstrated that pan-HDAC inhibitors enhanced H3K9 acetylation at the NEDD9 gene promoter by inhibiting the HDAC4-stimulated NEDD9-FAK signaling pathway, leading to breast cancer cell metastasis. This evidence concerns the gene HDAC9 and breast cancer.